
A new study linking attention-deficit hyperactivity disorder (ADHD) drugs and Parkinson’s disease could cause prescribers to re-think prescribing the medications.

A new study linking attention-deficit hyperactivity disorder (ADHD) drugs and Parkinson’s disease could cause prescribers to re-think prescribing the medications.

Healthcare experts detail three policies that MCOs should keep a close eye on.

Innovative PBM performance-based pharmacy networks focus on reducing costs and Improving clinical outcomes

These technology solutions on the market can treat chronic pain, allowing patients to eliminate or decrease their dependence on opioid drugs.


Here are the top 3 new approvals from FDA.

Here are five of the most promising healthcare technologies that will make your healthcare organization in step with the future.

In the managed healthcare market, words like logical, predictable, or stable are seldom used anymore. Instead, for healthcare executives, disruption is the norm.

A new study from Health Care Cost Institute has revealing findings about employer-sponsored insurance plans.

Payers challenged a 2014 CMS Overpayment Rule and won. Here’s what healthcare executives should know.

A Mayo Clinic study has surprising findings about how controlled substance agreements impact patients on long-term opioid therapy.

An Avalere analysis finds that this factor plays an important role in the era of value-based payment. Find out what it is.

While Teva Pharmaceutical’s new migraine prevention drug is unique, it faces competition from another major migraine treatment.

Pharmacy and healthcare experts cautiously praised the planned development of a fast-acting, better version of naloxone (Narcan), which is used to reverse the effects of opioid overdoses.

How would you define a specialty pharmaceutical? Chances are, it’s different from the way another healthcare executive would define them.

The hope is that more biosimilars will lead to more access and more affordable medications, but biosimilar uptake is lagging. Here’s why and how FDA hopes to fix it.

A new Swedish study examined gender differences in rheumatism and other autoimmune diseases. Here are the surprising findings.

Executives from diagnostics, payer, pharma, and patient care companies recently got together to share stakeholder insights on outcomes-based contracting.

Here’s what’s shaking up the drug launch pricing space. Experts weigh in.

Managed Healthcare Executive asked experts to identify Trump’s top priorities within the plan, and how those priorities could affect managed care.

Managed Healthcare Executive asked experts to weigh in on Trump’s new blueprint to tackle drug market challenges. Here’s what they said.

According to research-backed statistics, telepsychiatry improves the behavioral health outlook for today’s veterans.

Home-based palliative care helps ACOs manage fast-growing senior population with a serious or advanced illness, provide quality care, and generate cost savings that enable ongoing participation in the Medicare Shared Savings Program.

Managed Healthcare Executive asked healthcare executives about their interview techniques, how they approach job interviews, and the one doozy of a question that they like to ask job candidates. Here’s what they said.

FDA issued a recall of popular blood pressure drugs. Here’s what you need to know.

A new HealthMine survey of Medicare beneficiaries has surprising results about this population’s digital health literacy.

Payers are becoming more receptive to a different approach for paying for addiction treatment and recovery services, as evidenced by the formation of a new healthcare alliance that aims to redesign the structure and payment of these services.

If all consumers had a high understanding of how to navigate the healthcare system, health insurers could save billions of dollars a year. Here’s what you should do.

Making medications more affordable to patients is linked to better adherence, with no added costs, according to a new study.